Pharmaceutical - Pharmaceutical, Anti-Arthritics/Rheumatics

Filter

Popular Filters

1 to 25 of 212 results

Mundipharma launches monoclonal antibody Remsima in six European markets

26-02-2015

Privately-held UK-based drugmaker Mundipharma International is launching Remsima (infliximab) this month…

Anti-Arthritics/RheumaticsEuropeMarkets & MarketingMundipharmaPharmaceuticalRemsima

Sanofi collaborates with Lead Pharma for autoimmune disease development

Sanofi collaborates with Lead Pharma for autoimmune disease development

18-02-2015

French pharma major Sanofi has entered into a research collaboration and license agreement with privately-held…

Anti-Arthritics/RheumaticsLead PharmaLicensingPharmaceuticalResearchSanofi

CrystalGenomics signs agreement for Daewoong to commercialize Acelex in Korea

CrystalGenomics signs agreement for Daewoong to commercialize Acelex in Korea

09-02-2015

Korean biopharma company CrystalGenomics has signed a sales and marketing agreement with Daewoong Pharmaceutical…

AcelexAnti-Arthritics/RheumaticsCrystalGenomicsDaewoongLicensingPharmaceutical

Ligand out-licenses lasofoxifene to Sermonix

03-02-2015

USA-based drugmaker Ligand Pharmaceuticals has signed a license agreement with privately-held Sermonix…

Anti-Arthritics/RheumaticsFablynlasofoxifeneLicensingLigand PharmaceuticalsPharmaceuticalSermonix PharmaceuticalsUSAWomen's Health

AbbVie fourth-qtr beats forecasts, but posts Shire-associated $810 million loss

AbbVie fourth-qtr beats forecasts, but posts Shire-associated $810 million loss

31-01-2015

US drugmaker AbbVie on Friday announced financial results for the fourth quarter and full year 2014,…

AbbVieAnti-Arthritics/RheumaticsAnti-viralsFinancialHumiraPharmaceuticalViekira Pak

New drugs and biosimilars to drive rheumatoid arthritis to $19.3 billion by 2023

New drugs and biosimilars to drive rheumatoid arthritis to $19.3 billion by 2023

13-01-2015

The launch of novel drugs and biosimilars will drive steady growth in the global rheumatoid arthritis…

AmgenAnti-Arthritics/RheumaticsEnbrelHumiraMarkets & MarketingPharmaceuticalResearchUSA

Infinity Pharma to cease development on rheumatoid arthritis therapy after Phase II failure

Infinity Pharma to cease development on rheumatoid arthritis therapy after Phase II failure

09-01-2015

US pharma company Infinity Pharmaceuticals has reported that its Phase II study of duvesilib did not…

Anti-Arthritics/RheumaticsDuvesilibInfinity PharmaceuticalsPharmaceuticalResearchUSA

Sustained improvements for spondyloarthritis patients provided by Cimzia

22-12-2014

New data from the RAPID-axSpS study showed that the rapid improvements in clinical outcomes observed…

Anti-Arthritics/RheumaticsCimziaPharmaceuticalResearchUCB

Astellas Xtandi approved in Europe for new indication; Janssen deal update

03-12-2014

Japanese pharma major Astellas Pharma has received European Commission approval for a variation to amend…

Anti-Arthritics/RheumaticsASP015KAstellas PharmaEuropeJanssen BiotechJohnson & JohnsonLicensingMedivationOncologyPharmaceuticalRegulationXtandi

Positive Ph III data for AstraZeneca’s lesinurad in gout patients

17-11-2014

Anglo-Swedish pharma major AstraZeneca has presented positive top-line results of two pivotal Phase III…

allopurinolAnti-Arthritics/RheumaticsAstraZenecaInflammatory diseaseslesinuradPharmaceuticalResearch

Novartis announces positive results for secukinumab in psoriatic arthritis

Novartis announces positive results for secukinumab in psoriatic arthritis

17-11-2014

Swiss drug major Novartis has announced results from the pivotal Phase III FUTURE 1 and FUTURE 2 studies…

Anti-Arthritics/RheumaticsNovartisPharmaceuticalResearchsecukinumabSwitzerland

EMA responds to Ombudsman questioning of AbbVie trial redactions

13-11-2014

The European Medicines Agency says it has taken note of the European Ombudsman’s recent remarks on…

AbbVieAnti-Arthritics/RheumaticsEuropeHumiraPharmaceuticalRegulationResearch

Cut number of rheumatoid arthritis drugs and reduce side effects, says Belgian research

Cut number of rheumatoid arthritis drugs and reduce side effects, says Belgian research

10-11-2014

A two-year study into rheumatoid arthritis conducted at university hospitals in Belgium has shown that…

Anti-Arthritics/RheumaticsBelgiumLeflunomidemethotrexatePharmaceuticalResearch

UK's NICE does not recommend Pfizer's Xiapex for Dupuytren's contracture

UK's NICE does not recommend Pfizer's Xiapex for Dupuytren's contracture

07-11-2014

The UK’s National Institute for Health and Care Excellence is consulting on provisional recommendations…

Anti-Arthritics/RheumaticsPfizerPharmaceuticalRegulationUKXiapex

Rheumatologists have mixed views on Xeljanz's effect on structural damage and safety, but 80% prescribe it

Rheumatologists have mixed views on Xeljanz's effect on structural damage and safety, but 80% prescribe it

03-11-2014

Although 80% of rheumatologists surveyed by data and research firm Decision Resources Group prescribe…

Anti-Arthritics/RheumaticsBiosimilarsGlobalPfizerPharmaceuticalResearchXeljanz

AbbVie, still fuelled by Humira, beats own and analysts’ forecasts

AbbVie, still fuelled by Humira, beats own and analysts’ forecasts

01-11-2014

Just a couple of weeks after abandoning its $54 billion “tax inversion” motivated takeover of Ireland-headquartered…

AbbVieAnti-Arthritics/RheumaticsFinancialHumiraPharmaceuticalShireUSA

New Zealand proposal for sole supply of Remicade in DHB hospitals

New Zealand proposal for sole supply of Remicade in DHB hospitals

31-10-2014

Following a Request for Tender for infliximab issued on September 2, 2014 (RFT), New Zealand’s Pharmaceutical…

Anti-Arthritics/RheumaticsAntibiotics and Infectious diseasesceftaroline fosamilFinancialJanssen-CilagJohnson & JohnsonNew ZealandPharmaceuticalPricingRemicade

Novartis' secukinumab achieves primary endpoints in Phase III studies for ankylosing spondylitis

Novartis' secukinumab achieves primary endpoints in Phase III studies for ankylosing spondylitis

23-10-2014

Swiss drug major Novartis says its investigational drug AIN457 (secukinumab) has achieved the primary…

Anti-Arthritics/RheumaticsNovartisPharmaceuticalResearchsecukinumabSwitzerland

Horizon Pharma buys US rights to Nuvo’s Pennsaid for $45 million

19-10-2014

Canadian specialty drugmaker Nuvo Research says it has completed the sale of its osteoarthritis pain…

Anti-Arthritics/RheumaticsHorizon PharmaLicensingMallinckrodtNuvo ResearchPennsaidPharmaceuticalUSA

New Ph III data to support filing for AbbVie’s Humira in HS

13-10-2014

US pharma company AbbVie has reported new data with its mega blockbuster arthritis drug Humira (adalimumab)…

AbbVieAnti-Arthritics/RheumaticsDermatologicalsHumiraPharmaceuticalResearch

AbbVie gains expanded approval for Humira by FDA

AbbVie gains expanded approval for Humira by FDA

06-10-2014

US drugmaker AbbVie has received approval from the US Food and Drug Administration for an extension of…

AbbVieAnti-Arthritics/RheumaticsHumiraPharmaceuticalRegulationUSA

Lilly to drop Ph III tabalumab trial in lupus due to poor efficacy

Lilly to drop Ph III tabalumab trial in lupus due to poor efficacy

02-10-2014

US pharma major Eli Lilly has said it will discontinue development of tabalumab, which is being studied…

Anti-Arthritics/RheumaticsEli LillyImmunologicalsPharmaceuticalResearchtabalumabUSA

Novartis' secukinumab meets primary and secondary endpoints in Phase III psoriatic arthritis trials

Novartis' secukinumab meets primary and secondary endpoints in Phase III psoriatic arthritis trials

25-09-2014

Swiss drug major Novartis' AIN457 (secukinumab) has met the primary and key secondary endpoints in two…

Anti-Arthritics/RheumaticsDermatologicalsNovartisPharmaceuticalResearchsecukinumabSwitzerland

Opportunity for emerging agents in Crohn’s disease, report finds

Opportunity for emerging agents in Crohn’s disease, report finds

18-09-2014

New research from Decision Resources Group has found that only a small proportion of patients with Crohn's…

Anti-Arthritics/RheumaticsBiosimilarsEntyvioHumiraPharmaceuticalRemicadeResearchStelaraUSAXeljanz

1 to 25 of 212 results

COMPANY SPOTLIGHT

Menarini

Back to top